Oncology Examination: Difference between revisions

No edit summary
mNo edit summary
Line 14: Line 14:
==I Mental Function, Pain & Somatosensory Screening==
==I Mental Function, Pain & Somatosensory Screening==


Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system<ref name="Breast Cancer Cognitive Dysfunction">Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.</ref><ref>Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.</ref><ref>Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.</ref>&nbsp;Mental impairments can be indused by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage<ref>Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493</ref>. &nbsp;Emotional Functions may also affect the ability of our patients to respond to and/or participate in physical therapy.  
Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system<ref name="Breast Cancer Cognitive Dysfunction">Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.</ref><ref>Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.</ref><ref>Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.</ref>&nbsp;Mental impairments can be induced by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage<ref>Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493</ref>. &nbsp;Emotional Functions may also affect the ability of our patients to respond to and/or participate in physical therapy.  


== Diagnostic &amp; Screening Measures  ==
== Diagnostic &amp; Screening Measures  ==
Line 20: Line 20:
=== 1. &nbsp;Mental Status  ===
=== 1. &nbsp;Mental Status  ===


&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;The [http://www.rehabmeasures.org/lists/rehabmeasures/dispform.aspx?id=912 Mini-Mental State Examination Measure]<ref>Folstein M, Folstein S, McHugh P. Mini-Mental State: a practical method for grading the state of patients for the clinician J Psychiatr Res. 1975;12:189–198.</ref>&nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;The [https://physio-pedia.com/Mini-Mental_State_Examination mini-mental state examination measure]


&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;read more about the [http://www.rehabmeasures.org/lists/rehabmeasures/dispform.aspx?id=912 Link]
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Profile of Mood States<ref>Cella D, Tross S, Orov E, et al. Mood states of patients after the diagnosis of cancer. J Psychosoc Oncol. 1989;7:45–53.</ref>
 
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Profile of Mood States<ref>Cella D, Tross S, Orov E, et al. Mood states of patients after the diagnosis of cancer. J Psychosoc Oncol. 1989;7:45–53.</ref> [http://www.mhs.com/product.aspx?gr=cli&prod=poms&id=overview POMS]


&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  
Line 32: Line 30:
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;1. &nbsp;Visual Analog Scale  
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;1. &nbsp;Visual Analog Scale  


&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;2. &nbsp;Numeric Rating Scale  
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;2. &nbsp;[https://physio-pedia.com/Numeric_Pain_Rating_Scale Numeric Rating Scale]


&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;3. &nbsp;Faces Pain Scale  
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;3. &nbsp;Faces Pain Scale  


&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4. &nbsp;[http://medicine.iupui.edu/RHEU/Physicians/bpisf.pdf Brief Pain Inventory]<ref>Cleeland C. Measurement and prevalence of pain in cancer. Semin Oncol Nurs. 1985;1:87–92.</ref>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;4. &nbsp;[https://physio-pedia.com/Brief_Pain_Inventory_-_Short_Form Brief Pain Inventory]  


&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  
Line 44: Line 42:
==== a) &nbsp;Vestibular====
==== a) &nbsp;Vestibular====


May be affected by neoplasms such as a&nbsp;<span style="line-height: 1.5em;">Vestibular schwannoma which may cause unilateral dysfunction&nbsp;</span><span style="line-height: 1.5em;">or chemotherapy drugs such as&nbsp;</span>Cisplastin  
May be affected by neoplasms such as a&nbsp;<span style="line-height: 1.5em;">Vestibular schwannoma which may cause unilateral dysfunction&nbsp;</span><span style="line-height: 1.5em;">or chemotherapy drugs such as&nbsp;</span>Cisplastin. Dizziness Handicap Inventory Questionnaire--25 items assess the impact of disequilibrium on functional activities.<ref>Jacobson G, Newman C, Hunter L, Balzer G. Balance function test correlates of the Dizziness Handicap Inventory. J Am Acad Audiol. 1991;2:253–260.</ref>  
 
[http://www.southamptonhospital.org/Resources/10355/FileRepository/Forms/Dizziness%20Hanicap%20Inventory%20-%20English.pdf Dizziness Handicap Inventory Questionnaire]--25 items assess the impact of disequilibrium on functional activities.<ref>Jacobson G, Newman C, Hunter L, Balzer G. Balance function test correlates of the Dizziness Handicap Inventory. J Am Acad Audiol. 1991;2:253–260.</ref>  
 
==== b) &nbsp;Somatosensory  ====
==== b) &nbsp;Somatosensory  ====


Line 95: Line 90:
Balance Measures  
Balance Measures  


*Functional Reach  
*[https://physio-pedia.com/Functional_Reach_Test_(FRT) Functional Reach]
*Berg Balance Scale  
*[[Berg Balance Scale]]
*Standard Romberg Test  
*[https://physio-pedia.com/Romberg_Test Standard Romberg Test]
*Tandem Romberg Test  
*Tandem Romberg Test  
*Timed Get up &amp; Go Test
*[https://physio-pedia.com/Timed_Up_and_Go_Test_(TUG) Timed Get up and Go Test]


===Gait===
===Gait===
Line 149: Line 144:
#Vital signs (RR, HR, BP)  
#Vital signs (RR, HR, BP)  
#Oxygen Sautration  
#Oxygen Sautration  
#&nbsp;Aerobic Test--6 Minute Walk  
#&nbsp;Aerobic Test--[[Six Minute Walk Test / 6 Minute Walk Test|6 Minute Walk]]
#Dyspnea Scale  
#Dyspnea Scale  
#Borg Rating of Perceived Exertion<br>
#[https://physio-pedia.com/Borg_Rating_Of_Perceived_Exertion Borg Rating of Perceived Exertion]<br>


<br>  
<br>  
Line 219: Line 214:
*Karnofsky Performance Scale
*Karnofsky Performance Scale


&nbsp; &nbsp; &nbsp;&nbsp;A standard measure of the ability of adult patients with cancer to perform ordinary tasks. scores range from 0 to 100. A higher score &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; means the patient is better able to carry out daily activities  
&nbsp; &nbsp; &nbsp;&nbsp;A standard measure of the ability of adult patients with cancer to perform ordinary tasks. scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities  


*Barthel Index &nbsp;includes multiple components and diverse self-care activities. May be more responsive in rehabilitation.<br>&nbsp; Performance or self-report measure of independence in basic activities of daily living<br>
*Barthel Index &nbsp;includes multiple components and diverse self-care activities. May be more responsive in rehabilitation.<br>&nbsp; Performance or self-report measure of independence in basic activities of daily living<br>
Line 244: Line 239:
== References  ==
== References  ==


<references />  
<references />
 
[[Category:Oncology]]
[[Category:Oncology]]

Revision as of 02:49, 15 July 2020




Oncology Examination[edit | edit source]

Using the International Classification Framework Model for Assessment in Oncology Rehabilitation by Gilchrist LS, Galantino ML, Wampler M, et al.[1]  

I Mental Function, Pain & Somatosensory Screening[edit | edit source]

Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system[2][3][4] Mental impairments can be induced by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage[5].  Emotional Functions may also affect the ability of our patients to respond to and/or participate in physical therapy.

Diagnostic & Screening Measures[edit | edit source]

1.  Mental Status[edit | edit source]

              The mini-mental state examination measure

              Profile of Mood States[6]

                 

2.  Pain Assessment[edit | edit source]

                     1.  Visual Analog Scale

                     2.  Numeric Rating Scale

                     3.  Faces Pain Scale

                     4.  Brief Pain Inventory

                     

3.  Neurological Assessment Measure[edit | edit source]

a)  Vestibular[edit | edit source]

May be affected by neoplasms such as a Vestibular schwannoma which may cause unilateral dysfunction or chemotherapy drugs such as Cisplastin. Dizziness Handicap Inventory Questionnaire--25 items assess the impact of disequilibrium on functional activities.[7]

b)  Somatosensory[edit | edit source]

c)  Neuromusculoskeletal[edit | edit source]

1.  Peripheral Neuropathies: Chemotherapy induced

          modified Total Neuropathy Score[8]

2.  Anesthesia/Dysesthesias

         with compression or surgical dissection of nerves

3.  Motor Function Loss

         Radiation Plexopathy

II Neuromusculoskeletal Function (Movement Related Functional Assessment)[edit | edit source]

Posture[edit | edit source]

ROM[edit | edit source]

  • Scar tissue formation after surgical resections, chemotherapy or radiation therapy.  
  • Fibrosis after irradiation.

Strength[edit | edit source]

  • Muscle weaknesses from inflammatory intermediates produced by the tumor that are catabolic and cause muscle wasting (cachexia).
  • Surgical denervation or damage
  • Radiation & Chemotherapy can damage muscle or nerve tissue.  (Vinca alkaloids, taxanes and platinum agents)
  • Grip dynamometers
  • MMT

Balance[edit | edit source]

Balance Dysfunction can be caused from any of the following

  • sensory input
  • central processing of balance-related information
  • ROM limitations
  • orthostatic hypotension
  • muscle weakness
  • peripheral neuropathies from taxane


Balance Measures

Gait[edit | edit source]

  • Kinetmatic Analysis
  • Gait Speed Measurements

Gait Measures

  • Tinetti Balance & Gait Scale

III.  System Screening[edit | edit source]

Cardiovascular[edit | edit source]

  • Cardiotoxicity can be a late effect of chemotherapy due damage of the cardiac myoctyes ultimately resulting in congestive heart failure.
  • Radiation may scar the cardiac and coronary arteries resulting in restrictive coronary disease

Measures

  1. Echocardiogram to assess ventricular function, cardiac motion and output.

Hematologic[edit | edit source]

Immunologic[edit | edit source]

  • Damage to lymph vessels by tumor obstruction, surgical resection of lymph nodes, radiation leading to fibrosis of the lymph vessels

Measures

  1. Limb Circumfrence Measurements Pre-op and Post-op
  2. Water Displacement Method of measuring limb volume

Integumentary[edit | edit source]

       Uses Grades to assess severity of different conditions for example Lymphedema

Respiratory[edit | edit source]

  • Lung tumors may limit thoracic cavity expansion, compress the airways or reduce the surface area of the lung.  
  • Chemotherapy agents (beomycin, methotrexate and docetaxel may damage pneumocytes.  This reduces alveoli and air exchange.
  • Patients are then at risk for pneumonitis or fibrosis.

Measures[edit | edit source]

  1. Vital signs (RR, HR, BP)
  2. Oxygen Sautration
  3.  Aerobic Test--6 Minute Walk
  4. Dyspnea Scale
  5. Borg Rating of Perceived Exertion


IV.  Red and Yellow Flag Measures & Risk Patterns[edit | edit source]

Sites at Risk for Neural Compression

Brachial Plexus:  Breast & Lung Tumors

Lumbosacral Plexus:  Colorectal & Gynecological Tumors, Sarcomas & Lymphomas

Symptoms:  Unrelenting pain, worse at night progressing to focal sensory loss or weakness

Cancers that often metastasize to the Spine

  • Prostate
  • Breast
  • Lung 
  • Colon

Cancers that often present in the femur

  • Sarcoma

Cancer and Cancer Treatment increases risk for Osteonecrosis

  • Proximal or Distal Femur
  • Proximal Humerus
  • Jaw
  • Metatarsals

Other Risks

  • Osteoporosis
  • Neutropenia
  • Thrombocytopenia

V.  Functional Activities, Mobility & Self-Care[edit | edit source]

Measures[edit | edit source]

  • Functional Mobility Assessment

     requires patients to physically perform specific tasks and to answer questions, quantifying their level of function.

  • The Toronto Extremity Salvage Score, lower-extremity version

     is a self administered questionnaire that asks patients to indicate the level of difficulty they experience in dressing,grooming, mobility, work, sports, and leisure


Mobility Assessment

  • changing and maintaining body positions
  • carrying
  • moving and handling objects
  • walking
  • moving around using transportation


Self Care Measures

includes grooming, bathing and dressing

  • Karnofsky Performance Scale

      A standard measure of the ability of adult patients with cancer to perform ordinary tasks. scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities

  • Barthel Index  includes multiple components and diverse self-care activities. May be more responsive in rehabilitation.
      Performance or self-report measure of independence in basic activities of daily living


Shoulder Measures for Breast Cancer[9]

  • The Functional Assessment of Cancer Therapy Breast (FACT-B+4)
  • Disability of Arm, Shoulder and Hand (DASH) questionnaires.

VI.  Psychosocial[edit | edit source]

Consider the patients domestic life, interpersonal relations and major life areas.  

assess participation in or attending community activities, reduced job expectations, etc

Measures

  • Reintegration to Normal Living Index

     Measures adults' perception of their ability to resume life roles after trauma or illness

References[edit | edit source]

  1. Gilchrist LS, Galantino ML, Wampler M, et al. A framework for assessment in oncology rehabilitation. Phys Ther. 2009;89:286–306.
  2. Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.
  3. Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.
  4. Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.
  5. Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493
  6. Cella D, Tross S, Orov E, et al. Mood states of patients after the diagnosis of cancer. J Psychosoc Oncol. 1989;7:45–53.
  7. Jacobson G, Newman C, Hunter L, Balzer G. Balance function test correlates of the Dizziness Handicap Inventory. J Am Acad Audiol. 1991;2:253–260.
  8. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;61:fckLR1297–1300.
  9. Davies C, Ryans K, Levenhagen K, Perdomo M. Quality of Life and Functional Outcome Measures for Secondary Lymphedema in Breast Cancer Survivors. Rehabil Oncol Vol 32 (1)p. 7-12